-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical (600196.SH) Holdings Subsidiary's Drug Registration Application Accepted

Zhitongcaijing·01/08/2026 09:41:08
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., the holding subsidiary of the company, a drug registration application for furitinib butyrate capsules (project code: SAF-189, application category: chemical drug class 1; “this new drug” for short) was accepted by the National Drug Administration. The indication for this application is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK).

The new drug is an innovative small molecule chemical drug. In addition to the current declared indications, as of the announcement date (i.e. January 8, 2026), non-small cell lung cancer (ROS1+), has also completed phase II clinical research in China (excluding Hong Kong, Macao and Taiwan regions of China).